|
|
 Previous Article | Table of Contents | Next Article 
Phenotypic Consequences of Mutations in the Fanconi Anemia FAC Gene: An International Fanconi Anemia Registry Study
Alfred P. Gillio,
Peter C. Verlander,
S.D. Batish,
P.F. Giampietro, and
Arleen D. Auerbach
From the Laboratory of Human Genetics and Hematology, The Rockefeller University, New York, NY; the Department of Pediatric Hematology-Oncology, Tomorrow's Children Institute, Hackensack University Medical Center, NJ; and the Division of Human Genetics, New York Hospital-Cornell University Medical College, NY.
Fanconi anemia (FA) is a genetically and phenotypically heterogeneous disorder defined by cellular hypersensitivity to DNA cross-linking agents; mutations in the gene defective in FA complementation group C, FAC, are responsible for the syndrome in a subset of patients. We have performed an analysis of the clinical effects of specific mutations in the FAC gene. Using the amplification refractory mutation system assays that we developed to rapidly detect FAC mutations, at least one mutated copy of the FAC gene was identified in 59 FA patients from the International Fanconi Anemia Registry (IFAR). This represents 15% of the 397 FA patients tested. FA-C patients were divided into three subgroups based on results of a genotype-phenotype analysis using the Cox proportional hazards model: (1) patients with the IVS4 mutation (n = 26); (2) patients with at least one exon 14 mutation (R548X or L554P) (n = 16); and (3) patients with at least one exon 1 mutation (322delG or Q13X) and no known exon 14 mutation (n = 17). Kaplan-Meier analysis shows that IVS4 or exon 14 mutations define poor risk subgroups, as they are associated with significantly earlier onset of hematologic abnormalities and poorer survival compared to exon 1 patients and to the non-FA-C IFAR population. There was no direct correlation between the degree of cellular hypersensitivity to the clastogenic effect of diepoxybutane and severity of clinical phenotype. Sixteen of the 59 FA-C patients (27%) have developed acute myelogenous leukemia. Thirteen of these patients have died; AML was the cause of death in 46% of the expired FA-C patients. This study enables us to define this clinically heterogeneous disorder genotypically to better predict clinical outcome and aid decision-making regarding major therapeutic modalities for a subset of FA patients.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 105-110
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Dokal
Fanconi anemia is a highly penetrant cancer susceptibility syndrome
Haematologica,
April 1, 2008;
93(4):
486 - 488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Rosenberg, B. P. Alter, and W. Ebell
Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry
Haematologica,
April 1, 2008;
93(4):
511 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Berwick, J. M. Satagopan, L. Ben-Porat, A. Carlson, K. Mah, R. Henry, R. Diotti, K. Milton, K. Pujara, T. Landers, et al.
Genetic Heterogeneity among Fanconi Anemia Heterozygotes and Risk of Cancer
Cancer Res.,
October 1, 2007;
67(19):
9591 - 9596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Soulier, T. Leblanc, J. Larghero, H. Dastot, A. Shimamura, P. Guardiola, H. Esperou, C. Ferry, C. Jubert, J.-P. Feugeas, et al.
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway
Blood,
February 1, 2005;
105(3):
1329 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Guinan
Aplastic Anemia: Management of Pediatric Patients
Hematology,
January 1, 2005;
2005(1):
104 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Wagner
Practical and Ethical Issues with Genetic Screening
Hematology,
January 1, 2005;
2005(1):
498 - 502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Rosenberg, Y. Huang, and B. P. Alter
Individualized risks of first adverse events in patients with Fanconi anemia
Blood,
July 15, 2004;
104(2):
350 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Saadatzadeh, K. Bijangi-Vishehsaraei, P. Hong, H. Bergmann, and L. S. Haneline
Oxidant Hypersensitivity of Fanconi Anemia Type C-deficient Cells Is Dependent on a Redox-regulated Apoptotic Pathway
J. Biol. Chem.,
April 16, 2004;
279(16):
16805 - 16812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Kutler, B. Singh, J. Satagopan, S. D. Batish, M. Berwick, P. F. Giampietro, H. Hanenberg, and A. D. Auerbach
A 20-year perspective on the International Fanconi Anemia Registry (IFAR)
Blood,
February 15, 2003;
101(4):
1249 - 1256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M D Tischkowitz and S V Hodgson
Fanconi anaemia
J. Med. Genet.,
January 1, 2003;
40(1):
1 - 10.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. I. Kutler, A. D. Auerbach, J. Satagopan, P. F. Giampietro, S. D. Batish, A. G. Huvos, A. Goberdhan, J. P. Shah, and B. Singh
High Incidence of Head and Neck Squamous Cell Carcinoma in Patients With Fanconi Anemia
Arch Otolaryngol Head Neck Surg,
January 1, 2003;
129(1):
106 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Adachi, T. Oda, H. Yagasaki, K. Nakasato, T. Taniguchi, A. D. D'Andrea, S. Asano, and T. Yamashita
Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants
Hum. Mol. Genet.,
December 1, 2002;
11(25):
3125 - 3134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. D'Andrea, N. Dahl, E. C. Guinan, and A. Shimamura
Marrow Failure
Hematology,
January 1, 2002;
2002(1):
58 - 72.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Grompe and A. D'Andrea
Fanconi anemia and DNA repair
Hum. Mol. Genet.,
October 1, 2001;
10(20):
2253 - 2259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Wajnrajch, J. M. Gertner, Z. Huma, J. Popovic, K. Lin, P. C. Verlander, S. D. Batish, P. F. Giampietro, J. G. Davis, M. I. New, et al.
Evaluation of Growth and Hormonal Status in Patients Referred to the International Fanconi Anemia Registry
Pediatrics,
April 1, 2001;
107(4):
744 - 754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Faivre, P. Guardiola, C. Lewis, I. Dokal, W. Ebell, A. Zatterale, C. Altay, J. Poole, D. Stones, M. L. Kwee, et al.
Association of complementation group and mutation type with clinical outcome in Fanconi anemia
Blood,
December 15, 2000;
96(13):
4064 - 4070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Futaki, T. Yamashita, H. Yagasaki, T. Toda, M. Yabe, S. Kato, S. Asano, and T. Nakahata
The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients
Blood,
February 15, 2000;
95(4):
1493 - 1498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Ph. Guardiola, R. Pasquini, I. Dokal, J. J. Ortega, M. van Weel-Sipman, J. C. W. Marsh, S. E. Ball, F. Locatelli, C. Vermylen, R. Skinner, et al.
Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation
Blood,
January 15, 2000;
95(2):
422 - 429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Hoatlin, Y. Zhi, H. Ball, K. Silvey, A. Melnick, S. Stone, S. Arai, N. Hawe, G. Owen, A. Zelent, et al.
A Novel BTB/POZ Transcriptional Repressor Protein Interacts With the Fanconi Anemia Group C Protein and PLZF
Blood,
December 1, 1999;
94(11):
3737 - 3747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Awan, G. Malcolm Taylor, D. A. Gokhale, S. P. Dearden, A. Will, R. F. Stevens, J. M. Birch, and T. Eden
Increased Frequency of Fanconi Anemia Group C Genetic Variants in Children With Sporadic Acute Myeloid Leukemia
Blood,
June 15, 1998;
91(12):
4813 - 4814.
[Full Text]
[PDF]
|
|
|
|
|
